Hanseatic Management Services Inc. Makes New $581,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hanseatic Management Services Inc. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,153 shares of the biopharmaceutical company’s stock, valued at approximately $581,000.

A number of other institutional investors also recently modified their holdings of HALO. Whittier Trust Co. purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth $27,000. GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares during the period. International Assets Investment Management LLC purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at about $49,000. Finally, Toth Financial Advisory Corp purchased a new stake in shares of Halozyme Therapeutics in the third quarter worth about $57,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HALO. Benchmark reaffirmed a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. TD Cowen boosted their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Piper Sandler increased their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Morgan Stanley raised their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $61.75, for a total value of $617,500.00. Following the transaction, the senior vice president now owns 168,176 shares in the company, valued at approximately $10,384,868. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $61.75, for a total transaction of $617,500.00. Following the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at $10,384,868. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the transaction, the director now directly owns 69,874 shares in the company, valued at $4,031,729.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 89,881 shares of company stock valued at $5,169,834 over the last three months. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $60.63 on Thursday. The company has a market capitalization of $7.71 billion, a price-to-earnings ratio of 20.08, a PEG ratio of 0.53 and a beta of 1.29. The business has a 50 day moving average of $56.75 and a 200 day moving average of $52.48. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.68 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 3.84 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.